Chair of Ophthalmology
University of Chicago
Chicago, IL
The Impact of Biosimilars in Retinal Diseases
Experts discuss the use of biosimilars in treating neovascular age-related macular edema (nAMD) and diabetic macular edema (DME).
Read More
Safety Considerations for New Therapies
Experts discuss the safety of aflibercept 8 mg, emphasizing familiarity, efficacy, and durability, supported by reassuring data from the two-year PULSAR and PHOTON studies.
Perspectives on Loading Dose Recommendations for New Therapies
Experts discuss the practice of loading doses for newer agents and when they would consider this suitable for patients.
Perspectives on Retinal Fluid Management
Experts discuss the importance of fluid management, presenting a range of perspectives on managing complex cases.
Efficacy and Durability: New Therapies vs Aflibercept 2mg
Experts reflect on the current information available on the safety and durability of second-generation agents aflibercept 8 mg and faricimab.
Real-World Experiences With Aflibercept 8mg
Experts share their real-world experience with aflibercept 8 mg, comparing it to its predecessor, aflibercept 2 mg.
Real-World Experiences With Faricimab
Experts share their real-world experience with second-generation therapies, focusing on faricimab.
When to Switch to More Efficacious Agents
Experts discuss the timing of switching agents, particularly when switching to newer agents like aflibercept 8 mg or faricimab.
Choosing First-Line Therapy in nAMD or DME
Experts expand on the discussion of first-line therapy choice, discussing how insurance mandates may alter treatment paths and the importance of catering to patient goals.
Impact of First-Line Therapy on Long-Term Outcomes in nAMD and DME
Experts discuss the importance of optimizing first-line therapies in the treatment of retinal diseases like neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME).
